These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 39400749)

  • 1. PI3K/AKT/mTOR inhibitors for the management of triple-negative breast cancer.
    Altundag K
    Med Oncol; 2024 Oct; 41(11):279. PubMed ID: 39400749
    [No Abstract]   [Full Text] [Related]  

  • 2. PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer.
    Zhang HP; Jiang RY; Zhu JY; Sun KN; Huang Y; Zhou HH; Zheng YB; Wang XJ
    Breast Cancer; 2024 Jul; 31(4):539-551. PubMed ID: 38630392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Inhibition of the PI3K/Akt/mTOR Signaling Axis: Potential for Sarcoma Therapy.
    Wani AK; Singh R; Akhtar N; Prakash A; Nepovimova E; Oleksak P; Chrienova Z; Alomar S; Chopra C; Kuca K
    Mini Rev Med Chem; 2024; 24(16):1496-1520. PubMed ID: 38265369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
    Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
    J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.
    Alzahrani AS
    Semin Cancer Biol; 2019 Dec; 59():125-132. PubMed ID: 31323288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
    Ediriweera MK; Tennekoon KH; Samarakoon SR
    Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer.
    Pearson AD; DuBois SG; Macy ME; de Rojas T; Donoghue M; Weiner S; Knoderer H; Bernardi R; Buenger V; Canaud G; Cantley L; Chung J; Fox E; Friend J; Glade-Bender J; Gorbatchevsky I; Gore L; Gupta A; Hawkins DS; Juric D; Lang LA; Leach D; Liaw D; Lesa G; Ligas F; Lindberg G; Lindberg W; Ludwinski D; Marshall L; Mazar A; McDonough J; Nysom K; Ours C; Pappo A; Parsons DW; Rosenfeld A; Scobie N; Smith M; Taylor D; Weigel B; Weinstein A; Karres D; Vassal G
    Eur J Cancer; 2024 Aug; 207():114145. PubMed ID: 38936103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress.
    Bahrami A; Khazaei M; Shahidsales S; Hassanian SM; Hasanzadeh M; Maftouh M; Ferns GA; Avan A
    J Cell Biochem; 2018 Jan; 119(1):213-222. PubMed ID: 28513879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells.
    Chopra SS; Jenney A; Palmer A; Niepel M; Chung M; Mills C; Sivakumaren SC; Liu Q; Chen JY; Yapp C; Asara JM; Gray NS; Sorger PK
    Cell Syst; 2020 Jan; 10(1):66-81.e11. PubMed ID: 31812693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review.
    Singh P; Kumar V; Gupta SK; Kumari G; Verma M
    Med Oncol; 2021 Jan; 38(1):10. PubMed ID: 33452624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular alterations of PI3K/Akt/mTOR pathway: a therapeutic target in endometrial cancer.
    Pavlidou A; Vlahos NF
    ScientificWorldJournal; 2014; 2014():709736. PubMed ID: 24526917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer.
    Wen W; Marcinkowski E; Luyimbazi D; Luu T; Xing Q; Yan J; Wang Y; Wu J; Guo Y; Tully D; Han ES; Yost SE; Yuan Y; Yim JH
    Cells; 2019 Aug; 8(9):. PubMed ID: 31480338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis.
    van der Ploeg P; Uittenboogaard A; Thijs AMJ; Westgeest HM; Boere IA; Lambrechts S; van de Stolpe A; Bekkers RLM; Piek JMJ
    Gynecol Oncol; 2021 Nov; 163(2):433-444. PubMed ID: 34253390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.
    Wu P; Hu YZ
    Curr Med Chem; 2010; 17(35):4326-41. PubMed ID: 20939811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory Potential of Dietary Nutraceuticals on Cellular PI3K/Akt Signaling: Implications in Cancer Prevention and Therapy.
    Narayanankutty A
    Curr Top Med Chem; 2021; 21(20):1816-1831. PubMed ID: 34279200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.
    Barrett D; Brown VI; Grupp SA; Teachey DT
    Paediatr Drugs; 2012 Oct; 14(5):299-316. PubMed ID: 22845486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The PI3K/AKT/mTOR signaling pathway inhibitors enhance radiosensitivity in cancer cell lines.
    Mardanshahi A; Gharibkandi NA; Vaseghi S; Abedi SM; Molavipordanjani S
    Mol Biol Rep; 2021 Aug; 48(8):1-14. PubMed ID: 34357550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges.
    Khan MA; Jain VK; Rizwanullah M; Ahmad J; Jain K
    Drug Discov Today; 2019 Nov; 24(11):2181-2191. PubMed ID: 31520748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phytochemicals as PI3K/ Akt/ mTOR Inhibitors and Their Role in Breast Cancer Treatment.
    Narayanankutty A
    Recent Pat Anticancer Drug Discov; 2020; 15(3):188-199. PubMed ID: 32914720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of PI3K/Akt/mTOR signaling by natural products.
    Huang S
    Anticancer Agents Med Chem; 2013 Sep; 13(7):967-70. PubMed ID: 23272914
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.